Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis
Sponsor: Regeneron Pharmaceuticals
Summary
This study is researching a particular group of experimental drugs administered for a short period in the treatment of patients with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Official title: A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-12-22
Completion Date
2028-07-23
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
Vonsetamig
Administered as per the protocol
Odronextamab
Administered as per the protocol
Locations (6)
Mayo Clinic
Rochester, Minnesota, United States
University Medical Center of the Johannes Gutenberg-University Mainz
Mainz, Germany
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Changhua Christian Hospital
Changhua, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan